SYNEOS HEALTH UK LIMITED

The Life Sciences Industry Report 2025 explores AI's impact on healthcare and pharma, precision medicine, NGS, biomarkers, and clinical research challenges. It includes insights from Frontiers Health, a webinar on future health trends, and updates from the World Without Disease initiative.

DelveInsight's report forecasts the Neurotrophic Keratitis market to grow significantly by 2032, driven by increasing prevalence, awareness, and pipeline product launches. It covers epidemiology, market trends, and therapeutic developments in the 7MM, highlighting key companies and therapies.

Cure and Deerfield Management announce the 2025 XSeed Award, offering up to $250,000 each to two minority- or women-led NYC-based life science startups for novel drug development. Applications close February 28, 2025, with winners announced in May 2025, aiming to foster innovation and diversity in healthcare.

The Life Sciences BPO market is projected to grow from US$ 406.8 billion in 2023 to US$ 999 billion by 2033, at a 9.4% CAGR, driven by rising drug development costs, patent expirations, and the globalization of drug development. Asia-Pacific leads with a 37.8% market share, supported by skilled labor and government initiatives. Key trends include the integration of advanced technologies, emphasis on data security, and a shift towards personalized medicine.

The global clinical trials outsourcing market, valued at $46.15 billion in 2023, is projected to reach $70 billion by 2029, growing at a CAGR of 7.19%. North America dominates the market, driven by high clinical trial volumes and supportive FDA guidelines. Key players include Charles River Laboratories, ICON plc, and Syneos Health. The Functional Service Provider (FSP) model is gaining popularity for its cost-effectiveness and flexibility, offering tailored clinical trial solutions.

The clinical trial outsourcing market is expected to grow from $52.39 billion in 2023 to $111.01 billion by 2032, driven by a CAGR of 8.7%. Outsourcing offers cost savings, specialized expertise, and accelerated timelines, with emerging markets and technologies like AI enhancing efficiency and accessibility.

Syneos Health released its 2025 Health Trends Report, highlighting how data, tech, and empathy reshape healthcare, focusing on precision, personalization, and holistic models. Key trends include AI in rare disease research, FemTech advancements, predictive sales intelligence, precision psychiatry, deepened patient experience insights, emerging Medical Affairs roles, mainstreaming genetic medicine, diverse Real World Evidence, inclusive clinical trial teams, and expanded clinical research in Southeast Asia.

Resonance Health acquired TrialsWest for A$8M, expanding into clinical trial operations. Outsourcing clinical trials enhances efficiency, cost-effectiveness, and regulatory compliance, benefiting companies by optimizing resources and focusing on core activities.

Resonance Health acquired TrialsWest for A$8M, expanding into clinical trials. The global Clinical Trial Outsourcing market was valued at USD 52.39B in 2023 and is projected to reach USD 111.01B by 2032, with a CAGR of 8.7%. Outsourcing offers cost-effectiveness, faster timelines, and regulatory compliance, but faces challenges like rising costs and undisclosed expenses.

The biosimilars market is projected to grow from USD 36.01B in 2024 to USD 114.02B by 2031, at a CAGR of 17.9%. Factors driving growth include rising demand for cost-effective biologics and patent expirations. Key trends include regulatory approvals and new product launches. North America is expected to dominate due to favorable regulations.